While its use has been somewhat questioned due to adverse event concerns (115), a more recently-developed agent, lobeglitazone, exhibits improved safety with improvements in insulin sensitivity and liver steatosis in T2D-associated NAFLD (116). The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.